Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 130 results

ea0086ns1.1 | Neuroendocrine tumours | SFEBES2022

The management of neuroendocrine tumours

Grossman Ashley

Neuroendocrine tumours, or NETs, are a heterogeneous group of tumours which may arise from many sites, but primarily from the gastro-entero-pancreatic (GEP) system, and the respiratory system as bronchial and occasionally thymic NETs. Many small NETs are diagnosed incidentally as appendiceal or gastric NETs, and generally act in a totally benign manner. Diagnosis is contingent on positive histopathology (positive chromogranin immunostaining, grading 1-3 based on the Ki-67 inde...
0 shares

ea0059se1.3 | (1) | SFEBES2018

Why did the Queen die?

Grossman Ashley

In 1547 Henry VIII died, and was succeeded by his young son from his marriage to Jane Seymour; the boy was only 9 years old, and became Edward VI. However, he was a sickly child, and only survived to the age of 15 years, probably dying of TB. With no living male heir, there was an attempt at continuing with a Protestant monarch, but this lasted only 9-days with the unfortunate Lady Jane Grey. The crown then fell to Mary, the child of the marriage of Henry to Catherine of Arago...
0 shares

ea0038mte9 | (1) | SFEBES2015

Grossman Ashley

The term pituitary tumour usually implies an adenoma arising from anterior pituitary tissue, but in fact some 2–5% of ‘tumours’ in this region are not adenomas, and many of these arise from the para-sellar region or within the hypothalamus. One clue as to the non-adenomatous origin of such tumours is the presence of diabetes insipidus, which is almost never present with a primary pituitary adenoma. Some 1% of sellar masses are metastases, most often from the fre...
0 shares

ea0035gh1biog | The Geoffrey Harris Prize Lecture | ECE2014

Geoffrey Harris Prize Winner

Grossman Ashley

This prestigious prize is intended for established workers in the field of basic and clinical neuroendocrinology and is generously supported by Ipsen. This year’s recipient is Prof. Ashley Grossman. The prize will be presented as part of the ECE 2014 opening ceremony where Prof. Grossman will deliver his lecture. Prof. Grossman will also deliver two other lectures at future ESE scientific meetings. Further information can be found at <a href="http://www.ese-hormones.org/p...
0 shares

ea0032s17.1 | Medical treatment of endocrine malignancies - an update | ECE2013

Pituitary carcinoma

Grossman Ashley

Pituitary tumours have recently been shown to have a prevalence of around one in a 1000, but the overwhelming majority of these are benign and readily treated. Nevertheless, while the initial therapy of the majority of non-secreting macroadenomas is transsphenoidal surgery, these have a high tendency to recur; recurrence cannot at present be predicted by any histopathological markers. Indeed, some 50% of such adenomas will recur over 10 years, although this recurrence rate is ...
0 shares

ea0031mte6 | (1) | SFEBES2013

Malignant phaeochromocytomas

Grossman Ashley

The great majority of phaeochromocytomas are benign, but some 10–15% are found to be malignant, the proportion being higher when they are extra-adrenal, paragangliomas. Malignant behaviour is hard to predict, and there are few histopathological features that are consistently of use. There are novel biochemical and molecular markers, but none has proven to be as yet especially reliable although elevated urinary methoxytyramine seems to be useful. At present, size is proba...
0 shares

ea0020s21.4 | Current problems in the management of pituitary tumours | ECE2009

Treatment options for aggressive pituitary tumors

Grossman Ashley

Pituitary tumours have recently been shown to have a prevalence of around one in a 1000, but the overwhelming majority of these are benign and readily treated. Nevertheless, while the initial therapy of the majority of non-secreting macroadenomas is transsphenoidal surgery, these have a tendency to recur even when apparently totally removed. Recurrence seems not to depend on dural invasion, and it cannot at present be predicted by any histopathological markers. Indeed, some 50...
0 shares

ea0050se1.4 | (1) | SFEBES2017

You think you understand ACTH and Cushing’s syndrome?

Lowry Philip , Grossman Ashley , White Anne

The majority of patients with Cushing’s syndrome are ACTH-dependent, but the diagnosis of ACTH-dependence, and then the differential diagnosis between Cushing’s disease and the ectopic ACTH syndrome, is dependent on the measurement of ACTH. In the mammalian adult anterior pituitary, POMC is cleaved into a variety of products including the ‘normal’ ACTH(1-39). In the pars intermedia (present in the human fetus and most mammals), ACTH is cleaved further by th...
0 shares

ea0050se1.4 | (1) | SFEBES2017

You think you understand ACTH and Cushing’s syndrome?

Lowry Philip , Grossman Ashley , White Anne

The majority of patients with Cushing’s syndrome are ACTH-dependent, but the diagnosis of ACTH-dependence, and then the differential diagnosis between Cushing’s disease and the ectopic ACTH syndrome, is dependent on the measurement of ACTH. In the mammalian adult anterior pituitary, POMC is cleaved into a variety of products including the ‘normal’ ACTH(1-39). In the pars intermedia (present in the human fetus and most mammals), ACTH is cleaved further by th...
0 shares

ea0044p134 | Neoplasia, cancer and late effects | SFEBES2016

Somatastatin analogue tolerability testing in the management of neuro endocrine tumours (NETs), a single centre review of practice

Tadman Michael , Charlton Philip , Grossman Ashley

Background and aims: Immediate release somatostatin analogues (SAs) have routinely been administered to test tolerability prior to commencing long-acting SAs, though there is limited evidence to support this process. We aim to examine this practice at our centre.Methods: Patients who received SA therapy for a neuro endocrine tumours (NET) between December 2012 and December 2014 were identified. Records were used to identify; start date, duration of test-...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more